Health Care/Hospital

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the disc...

2026-10-23 08:02 2418

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011,will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These p...

2026-10-23 08:00 1936

Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration

Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboration for patients and communities in Hong Kong. The partnership will help strengthen clinical research, develop future healthcare talent and su...

2026-10-22 23:52 3503

Tairex Launches Multi-Agent AI System to Transform Clinical Collaboration and Decision Support

BEIJING, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, unveiled the Multidisciplinary Human-Agent Collaboration (MHAC) Ecosystem for Agent Hospital, designed to enable spec...

2026-10-22 23:00 1804

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

* GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. * Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, It...

2026-10-22 22:30 3395

New hair transplant review challenges fixed donor limits

Patient-specific assessment helps us identify additional donor options while recognizing areas that should be avoided

2026-10-22 22:05 1633

ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow

The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract Workflow in the Japanese market, supporting good visual outcomes for patients. JENA, Germany and TOKYO, Oct. 22, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today the commercial availability of th...

2026-10-22 21:00 1299

Vespexx Recognized as Finalist for the Digital Health Hub Foundation Digital Health & AI Awards 2026 at HLTH

SEOUL, South Korea, Oct. 22, 2026 /PRNewswire/ -- Vespexx Inc., an AI-driven femtech company,today announced it has been named a Finalist for the Digital Health Hub Foundation's Digital Health & AI Awards 2026, held at HLTH. Competing in the Rising Star track under the Women's & Family Health cat...

2026-10-22 21:00 3129

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S.C., Oct. 22, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmace...

2026-10-22 20:00 1663

Ping An Unveils China's First Brain Health Service Management Program, Focused on Alzheimer's Prevention and Care

HONG KONG and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Ping An Insurance (Group) Company of China ("Ping An") unveiled China's first Brain Health Service Management Program at a seminar in Beijing on proactive Alzheimer's management and brain health services. At the event, Ping An ...

2026-10-22 18:12 3280

HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

* Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity * Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational...

2026-10-22 18:00 1908

Tairex Launches Multi-Agent AI System to Transform Clinical Collaboration and Decision Support

BEIJING, Oct. 22, 2026 /PRNewswire/ -- Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University,unveiled on October 21 the Multidisciplinary Human-Agent Collaboration (MHAC) Ecosystem for Agent Hospital, designed to enable speci...

2026-10-22 17:00 1743

[China's Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures

SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Neurointerventional robots have long remained at the stage of "only being able to assist with angiography." Through close medical-engineering collaboration with Professor Jianmin Liu's team at Shanghai Changhai Hospital, Shenzhen Institute of Advanced Biome...

2026-10-22 14:11 1727

Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission

SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA...

2026-10-22 13:30 1730

NUH WINS GOLD AT IHF AWARDS 2026 FOR GREEN OPERATING THEATRE PROGRAMME

 NUH won Gold and received an Honourable Mention for its sustainability efforts at the International Hospital Federation Awards 2026, alongside presentations of its green surgical initiatives, digital health and organisational improvement initiatives at the World Hospital Congress. SINGAPORE, Oc...

2026-10-22 09:27 4250

Taimei Technology and GreenLight Clinical Expand Strategic Partnership at AusBiotech 2026 to Pioneer AI-Native Trial Execution Across Asia-Pacific

GOLD COAST, Australia, Oct. 22, 2026 /PRNewswire/ -- Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded strategic partnership at AusBiotech 2026. Evolvi...

2026-10-22 08:00 3481

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an ...

2026-10-22 02:01 2726

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

* The study evaluates patients with liver cancer at high risk of recurrence following surgical resection * Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focus...

2026-10-21 21:10 4212

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

* Becomes the 7th International Registrational Clinical Trial for Ivonescimab * Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its ...

2026-10-21 20:42 2169

Axtria Wins 2026 Minsky Award for Excellence in AI for the Third Consecutive Year

AI-powered Next Best Action solution generated more than $180 million in incremental revenue for a brand for a global pharmaceutical leader BERKELEY HEIGHTS, N.J., Oct. 21, 2026 /PRNewswire/ -- Axtria Inc.

2026-10-21 20:15 1630
12345 ... 845